DUBLIN--(BUSINESS WIRE)--The "COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.
“COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Product Landscape, 2021”Tweet this
“COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Product Landscape, 2021”
The report provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
COVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples.
Scope
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
Overview
3 Products under Development
3.1 Pipeline Products by Stage of Development
3.2 Pipeline Products by Territory
3.3 Pipeline Products by Regulatory Path
3.4 Pipeline Products by Estimated Approval Date
3.5 Ongoing Clinical Trials
4 Pipeline Products under Development by Companies
4.1 Pipeline Products by Stage of Development
5 COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Companies and Product Overview
6 Appendix
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/2nfxc5
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900